BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin K, Zahlanie Y, Ortwine JK, Mang NS, Wei W, Brown LS, Prokesch BC. Decreased Outpatient Fluoroquinolone Prescribing Using a Multimodal Antimicrobial Stewardship Initiative. Open Forum Infect Dis 2020;7:ofaa182. [PMID: 32548204 DOI: 10.1093/ofid/ofaa182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 St Louis J, Okere AN. Clinical impact of pharmacist-led antibiotic stewardship programs in outpatient settings in the United States: A scoping review. Am J Health Syst Pharm 2021;78:1426-37. [PMID: 33889930 DOI: 10.1093/ajhp/zxab178] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Jensen KL, Rivera CG, Draper EW, Ausman SE, Anderson BJ, Dinnes LM, Christopherson DR, Prigge KA, Rajapakse NS, Vergidis P, Virk A, Stevens RW. From concept to reality: Building an ambulatory antimicrobial stewardship program. J Am Coll Clin Pharm 2021;4:1583-93. [DOI: 10.1002/jac5.1528] [Reference Citation Analysis]
3 Buehrle DJ, Wagener MM, Clancy CJ. Outpatient Fluoroquinolone Prescription Fills in the United States, 2014 to 2020: Assessing the Impact of Food and Drug Administration Safety Warnings. Antimicrob Agents Chemother 2021;65:e0015121. [PMID: 33875430 DOI: 10.1128/AAC.00151-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Vermeulen H, Coenen S, Hens N, Bruyndonckx R. Impact of changing reimbursement criteria on the use of fluoroquinolones in Belgium. J Antimicrob Chemother 2021:dkab255. [PMID: 34374778 DOI: 10.1093/jac/dkab255] [Reference Citation Analysis]
5 Livorsi DJ, Suda KJ, Cunningham Goedken C, Hockett Sherlock S, Balkenende E, Chasco EE, Scherer AM, Goto M, Perencevich EN, Goetz MB, Reisinger HS; Veterans Affairs-Centers for Disease Control and Prevention Practice-Based Research Network. The feasibility of implementing antibiotic restrictions for fluoroquinolones and cephalosporins: a mixed-methods study across 15 Veterans Health Administration hospitals. J Antimicrob Chemother 2021;76:2195-203. [PMID: 34015115 DOI: 10.1093/jac/dkab138] [Reference Citation Analysis]
6 Pédeboscq S, Issa N, Lahouati M, Labadie A, Pereyre S, Camou F. Impact of a 5-year antimicrobial stewardship program focusing on fluoroquinolone prescriptions. Int J Pharm Pract 2021;29:616-21. [PMID: 34355739 DOI: 10.1093/ijpp/riab047] [Reference Citation Analysis]
7 Umarje SP, Alexander CG, Cohen AJ. Ambulatory Fluoroquinolone Use in the United States, 2015-2019. Open Forum Infect Dis 2021;8:ofab538. [PMID: 34901300 DOI: 10.1093/ofid/ofab538] [Reference Citation Analysis]
8 Valentine-king M, Van J, Hines-munson C, Dillon L, Graber CJ, Patel PK, Drekonja D, Lichtenberger P, Shukla B, Kramer J, Ramsey D, Trautner B, Grigoryan L. Identification of Novel Factors Associated with Inappropriate Treatment of Asymptomatic Bacteriuria in Acute and Long-term Care. American Journal of Infection Control 2022. [DOI: 10.1016/j.ajic.2022.02.010] [Reference Citation Analysis]